Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with esophageal brachytherapy in locally recurrent esophageal cancer
ChiCTR2600121946Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab and tuvonralimab in esophageal cancer, Esophageal Squamous Cell Carcinoma (ESCC) and esophageal adenocarcinoma (EAC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Radiation dose exploration stage: Recommended Phase 2 dose (RP2D) and Objective Response Rate (ORR) evaluated by investigators. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on ChiCTR2600121946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121946.